Ventyx Biosciences VTYX 深 沪
已收盘 03-04 16:00:00 美东时间
14.00
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 14.00
- 总市值 100.47万
- 52周最高 25.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.783
- 委 比 0.00%
- 总股本 7.18万
- 历史最高 47.2508
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.783
- 每 手 1
- 风险率 4.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
Equillium reported Q1 2026 financial results with $61.3M in cash and plans to initiate a Phase 1 study for EQ504 in mid-2026. Snehal Naik, Ph.D., was appointed Chief Development Officer, bringing extensive experience in immunology and clinical development. EQ504, a potent AhR modulator, showed promising preclinical data supporting its potential for treating ulcerative colitis and other inflammatory diseases. The company also highlighted progress ...
05-13 20:01
礼来(LLY.US)拟豪掷超20亿美元拿下Kelonia 加码血液肿瘤赛道
礼来正就收购私营生物技术公司Kelonia Therapeutics展开深入谈判，交易估值超过20亿美元。
04-20 07:40
Eli Lilly nears $2B-plus deal for Kelonia to expand cancer pipeline: WSJ
Eli Lilly (LLY) is in advanced negotiations to acquire Kelonia Therapeutics in a transaction valued at more than $2 billion, The Wall Street Journal reported Sunday, citing people familiar with the di...
04-20 06:08
Eli Lilly Expands Into Sleep Medicine With Centessa Buyout
Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.
03-31 22:48
UPDATE 2-Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet
UPDATE 2-Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet Adds details throughout March 31 (Reuters) - Eli Lilly LLY.N said on Tuesday it would buy Centessa Pharmaceuticals 260y.F in a deal valued at up to $7.8 billion as the U.S. drugmaker looks to diversify beyond its metabol
03-31 19:08
Ventyx Biosciences Completes Cash Merger and Equity Payout
Ventyx Biosciences ( ($VTYX) ) has shared an update. On the closing date of a p...
03-04 22:49
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Oppenheimer Downgrades Ventyx Biosciences to Perform
Oppenheimer analyst Jeff Jones downgrades Ventyx Biosciences (NASDAQ:VTYX) from Outperform to Perform.
01-09 02:05
Alphabet To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-08 21:13
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
